HOME >> BIOLOGY >> NEWS
Mouse model advances understanding of synovial sarcoma

A mouse model for synovial sarcoma has enabled scientists to make tremendous progress toward understanding the origin and pathogenesis of this highly aggressive soft-tissue malignancy. The research, published in the April issue of the journal Cancer Cell, published by Cell Press, provides new information about the timing and environment required for initiation and progression of synovial sarcoma. The mouse model is also likely to serve as an invaluable resource for development of successful therapeutic strategies for this often lethal cancer.

Synovial sarcoma is associated with expression of a chimeric fusion protein called SYT-SSX. Dr. Mario R. Capecchi, from the Howard Hughes Medical Institute and the Department of Human Genetics at the University of Utah School of Medicine, and colleagues developed a mouse model that expresses human SYT-SSX in chosen target cells. Using this approach, the researchers discovered that, although it is named for its common proximity to limb joints, this tumor appears to arise from skeletal muscle precursor cells called myoblasts. Remarkably, expression of SYT-SSX in myoblasts was sufficient to induce synovial sarcoma with an astonishing 100% penetrance.

Use of a sophisticated conditional genetic technique allowed the researchers to control the timing of fusion protein expression so as to examine what happens when the protein is expressed at different stages of muscle development. Earlier expression of SYT-SSX disrupted normal development and was associated with embryonic lethality, while expression in more differentiated muscle cells induced significant muscle cell damage and death in the absence of tumor formation.

Further studies demonstrated that this mouse model of synovial sarcoma faithfully recapitulates human synovial sarcoma on multiple levels. As in the human cancer, tumors in the mice arise most commonly in close proximity to joints. The researchers speculate that the cartilage associa
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
9-Apr-2007


Page: 1 2

Related biology news :

1. Mouse FH knockout resembles human renal cell cancer
2. Mouse stem cell line advance suggests potential for IVF-incompetent eggs
3. Mouse model underestimates the critical role of Tyk2 in human immune system
4. Mouse DNA to aid biomedical research
5. Mouse strain with gene stutter will help leukemia research
6. Knockout Mouse Project
7. NIH launches Knockout Mouse Project
8. Mouse mimics chronic leukemia, will aid drug development
9. Mouse, frog and bird put Snail and Slug to different uses
10. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk
11. Mouse to man: The story of chromosomes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... -- BioCatch , the global leader in behavioral biometrics, ... grew to over 40 granted and pending patents. ... , , The Company,s IP ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... costly hardware components needed to estimate the force and pressure applied to ...
(Date:12/7/2016)... 2016   Veridium , a leader in ... new CEO James Stickland . Stickland, a ... experience, has served in senior executive roles for ... in expanding a pipeline of venture capital and ... recently served as managing director of U.K.-based fintech ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... 2017 , ... DaVita Clinical Research (DCR), a ... device development, and Prism Clinical Research , a leader in providing fully ... Clinical Trials (VCT) has been selected by both companies as an exclusive ...
(Date:1/18/2017)... Portland, OR (PRWEB) , ... January 18, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... Altera Cyclone V E FPGA into a compact business-card sized form factor suitable ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive ... 2017 in its continued commitment to the advancement of the clinical trials segment. ... issues related to clinical trial planning and management. , As executive talent ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Researchers from a new study are ... fall low enough after prostate cancer treatment, this indicates there is still remaining prostate cancer ... mortality. , “ The PSA test has always been an indicator of whether a man’s ...
Breaking Biology Technology:
Cached News: